Imperial College London
Alternate

ProfessorSebastianJohnston

Faculty of Medicine, National Heart & Lung Institute

Asthma UK Clinical Chair
 
 
 
//

Contact

 

+44 (0)7931 376 544s.johnston

 
 
//

Assistant

 

Mr Christophe Tytgat +44 (0)20 7594 3849

 
//

Location

 

343Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Johnston:2020:10.1101/2020.10.27.20220509,
author = {Johnston, SL and McKay, PF and Kebadze, T and Hu, K and Samnuan, K and Aniscenko, J and Cameron, A and Patel, N and Randell, P and Shattock, RJ and Edwards, MR},
doi = {10.1101/2020.10.27.20220509},
title = {Evaluation of the Abbott Architect, Roche Elecsys and Virtus S1 SARS-CoV-2 antibody tests in community-managed COVID-19 cases},
url = {http://dx.doi.org/10.1101/2020.10.27.20220509},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Antibody testing can help define how protective immunity to SARS-CoV-2 is and how long this immunity lasts. Many antibody tests have been evaluated in hospitalised rather than community based COVID-19 cases. Virtus Respiratory Research Ltd (Virtus) has developed its own quantitative IgM and IgG SARS CoV-2 antibody assay. We report its validation and performance characteristics and compare its performance with the Abbott Architect and Roche Elecsys assays in community COVID cases.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We developed a quantitative antibody test to detect IgM and IgG to the SARS-CoV-2 S1 spike protein (the Virtus test) and validated this test in 107 “true positive” sera from 106 community-managed and 1 hospitalised COVID-19 cases and 208 “true negative” serum samples. We validated the Virtus test against a neutralising antibody test. We determined sensitivities of the Abbott test in the 107 true positive samples and the Roche test in a subset of 75 true positive samples.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The Virtus quantitative test was positive in 93 of 107 (87%) community cases of COVID-19 and both IgM and IgG levels correlated strongly with neutralising antibody titres (r=0.75 for IgM, r=0.71 for IgG, <jats:italic>P</jats:italic><0.0001 for both antibodies). The specificity of the Virtus test was 98.6% for low level antibody positives, 99.5% for moderate positives and 100% for high or very high positives. The Abbott test had a sensitivity of 68%. In the 75 sample subset, the Virtus test was positive in 91%, the Roche test in 69%.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The Abbott and R
AU  - Johnston,SL
AU  - McKay,PF
AU  - Kebadze,T
AU  - Hu,K
AU  - Samnuan,K
AU  - Aniscenko,J
AU  - Cameron,A
AU  - Patel,N
AU  - Randell,P
AU  - Shattock,RJ
AU  - Edwards,MR
DO  - 10.1101/2020.10.27.20220509
PY  - 2020///
TI  - Evaluation of the Abbott Architect, Roche Elecsys and Virtus S1 SARS-CoV-2 antibody tests in community-managed COVID-19 cases
UR  - http://dx.doi.org/10.1101/2020.10.27.20220509
ER  -
Download